| Code | CSB-RA878931MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to lirentelimab, targeting SIGLEC8 (Sialic acid-binding Ig-like lectin 8), a cell surface receptor selectively expressed on human eosinophils, mast cells, and basophils. SIGLEC8 functions as an inhibitory receptor that, upon engagement, triggers apoptosis in eosinophils and inhibits mediator release from mast cells. This receptor plays a critical role in regulating type 2 inflammatory responses and has emerged as a therapeutic target for eosinophil-associated and mast cell-mediated disorders, including eosinophilic gastrointestinal diseases, chronic urticaria, severe asthma, and allergic conditions.
Lirentelimab is a non-fucosylated humanized IgG1 anti-SIGLEC8 monoclonal antibody that has been investigated in clinical trials for conditions such as eosinophilic gastritis, eosinophilic esophagitis, and chronic spontaneous urticaria. This biosimilar antibody provides researchers with a valuable tool for investigating SIGLEC8-mediated immune regulation, studying eosinophil and mast cell biology, and exploring potential therapeutic mechanisms in allergic and inflammatory disease models.
There are currently no reviews for this product.